Concepedia

Author

Urban Scheuring

Goethe University FrankfurtORCID

Also Known As

U J Scheuring, U Scheuring, U. J. Scheuring, U. Scheuring, URBAN J. SCHEURING, Urban J Scheuring, Urban J. Scheuring, Urban Scheuring

65

Publications

3.3K

Citations

23

H-Index

64

Concepts

All Affiliations

Goethe University FrankfurtColumbia University Irving Medical CenterAstraZeneca (United Kingdom)Samsung Medical CenterUniversity Hospital of Lausanne
US

About

Urban Scheuring is an author at Goethe University Frankfurt specializing in medicine, immunology, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

14

14

656

2

Health Sciences

3

3

277

3

Natural Sciences

1

1

14

4

Allergy

1

1

56

5

Blood Transplantation

1

1

25

Urban Scheuring

×

30

Publications

3.2K

Citations

22

H-Index

YearCitations

Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer

Naiyer A. Rizvi, Byoung Chul Cho, Niels Reinmuth,

JAMA Oncology

2020

616

Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia

Monika Brüggemann, Thorsten Raff, Thomas Flohr,

Blood

2005

534

Randomized Phase II Trial of First-Line Treatment With Sorafenib Versus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma

Bernard Escudier, Cezary Szczylik, Thomas E. Hutson,

Journal of Clinical Oncology

2009

489

Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)

Michael Stadler, Martin Bornhäuser, Gesine Bug,

Blood

2005

199

ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer

David Planchard, Niels Reinmuth, Jürgen R. Fischer,

Annals of Oncology

2020

156

Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: Final results

Cezary Szczylik, Tomasz Demkow, Michael Staehler,

Journal of Clinical Oncology

2007

138

A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study

Han Si, Michael Kuziora, Katie Quinn,

Clinical Cancer Research

2020

109

Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate.

Wolf‐Karsten Hofmann, Martina Komor, Urban Scheuring,

PubMed

2003

107

Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL)

Urban Scheuring, SA Klein, Nicola Gökbuget,

Leukemia

2002

81

Abstract CT074: Tumor mutational burden (TMB) as a biomarker of survival in metastatic non-small cell lung cancer (mNSCLC): Blood and tissue TMB analysis from MYSTIC, a Phase III study of first-line durvalumab ± tremelimumab vs chemotherapy.

Solange Peters, Byoung Chul Cho, Niels Reinmuth,

Cancer Research

2019

76

Page 1